New agent competes with triple therapy in H. pylori eradication

    loading  Checking for direct PDF access through Ovid

Abstract

With recent results showing thatHelicobacter pylorieradication really does prevent stomach ulcers, Glaxo could be onto a winner with their new agent, ranitidine bismuth citrate. This single chemical molecule has been developed for use as monotherapy or in combination with antibacterials, and is likely to provide fierce competition for the currently-used triple therapy. Glaxo plans to file for regulatory approval for this drug later this year.

Related Topics

    loading  Loading Related Articles